Unknown NA INTERVENTIONAL 2-arm NCT05233293

Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma

Comparison of SpyGlass Guided RFA On The Same Stage Versus RFA After Cytobrush for Extrahepatic Cholangiocarcinoma

Sponsor: First People's Hospital of Hangzhou

Conditions Extrahepatic Cholangiocarcinoma Malignant Biliary Obstruction

Interventions Cytobrush + RFA Spyglass + RFA

Updated 7 times since 2022 Last updated: Aug 13, 2023 Started: Jan 1, 2021 Primary completion: Oct 1, 2023 Completion: Oct 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Extrahepatic Cholangiocarcinoma and Malignant Biliary Obstruction and is currently ongoing. First People's Hospital of Hangzhou leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Oct 2025 — Present [monthly]

Unknown NA

Status: Enrolling By Invitation → Unknown
Sep 2024 — Oct 2025 [monthly]

Enrolling By Invitation NA
Jul 2024 — Sep 2024 [monthly]

Enrolling By Invitation NA
Sep 2023 — Jul 2024 [monthly]

Enrolling By Invitation NA
Mar 2023 — Sep 2023 [monthly]

Enrolling By Invitation NA

▶ Show 2 earlier versions

Sep 2022 — Mar 2023 [monthly]

Enrolling By Invitation NA
Mar 2022 — Sep 2022 [monthly]

Enrolling By Invitation NA

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First People's Hospital of Hangzhou

Data source: First People's Hospital of Hangzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China